An injectable HIV-prevention drug is highly effective - NBC News
Thrilled over the news Thursday that lenacapavir was 89% more effective at preventing HIV than daily oral preventive medication among gay, bisexual and transgender people, plus previous...
Twice-yearly shot proves successful at preventing HIV infection …
Jul 24, 2024 · Phase 3 trial data shows that a twice-yearly injection of the drug lenacapavir can provide total protection against HIV infections. Two shots a year of a drug currently used to treat HIV...
Gileads Twice Yearly Lenacapavir Demonstrated 100 Efficacy and ...
Jun 20, 2024 · PURPOSE 1 met its key efficacy endpoints of superiority of twice-yearly lenacapavir to once-daily oral Truvada ® (emtricitabine 200mg and tenofovir disoproxil fumarate 300mg; F/TDF) and background HIV incidence (bHIV).
WHO announces the development of new guidelines for lenacapavir …
Jan 6, 2025 · WHO has convened a Guideline Development Group (GDG) for the development of new guidelines on the use of injectable lenacapavir as pre-exposure prophylaxis (PrEP) for HIV, and the optimization of HIV testing services for long-acting prevention products.
Long-acting injectable lenacapavir continues to show promising …
Sep 26, 2024 · WHO welcomes the latest findings from the PURPOSE-2 trial on long-acting injectable lenacapavir (LEN) for HIV prevention. An interim analysis, announced on 12 September 2024, demonstrated the drug’s remarkable efficacy in preventing HIV.
Anti-HIV drug lenacapavir called 'breakthrough of the year ... - NPR
Dec 12, 2024 · But 2024 has fueled increasing optimism among leading infectious disease experts after the results of two groundbreaking clinical trial results for a drug called lenacapavir showed it to be...
Twice-a-year injection reduced risk of HIV infection by 96%, drug …
Sep 12, 2024 · In a Phase 3 clinical trial, 99.9% of participants who took a twice-a-year injection of lenacapavir for HIV prevention did not acquire an infection, according to data from drugmaker Gilead...
New HIV drug can only offer hope of ending AIDS if all have …
GENEVA, 10 July 2024— UNAIDS has welcomed the release of Gilead Sciences’ trial results on the injectable long-acting HIV medicine Lenacapavir for HIV prevention.
Lenacapavir: The 'Breakthrough Of The Year' Drug For HIV Care
Dec 30, 2024 · A significant breakthrough in treating the Human Immunodeficiency Virus (HIV) came recently with the US Federal Drug Administration (FDA) approving lenacapavir, a new prototype medication.
Sunlenca® (lenacapavir) Receives FDA Approval as a First-in-Class ...
Dec 22, 2022 · Lenacapavir is being developed as a foundation for Gilead’s future HIV therapies with the goal of offering several long-acting options that help address individual needs and preferences that may help optimize outcomes and reduce burden of care.